{"nctId":"NCT02813265","briefTitle":"Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease","startDateStruct":{"date":"2016-06","type":"ACTUAL"},"conditions":["Dry Eye Syndromes","Keratoconjunctivitis Sicca"],"count":918,"armGroups":[{"label":"KPI-121 0.25% Ophthalmic Suspension","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: KPI-121 0.25% Ophthalmic Suspension"]},{"label":"Vehicle of KPI-121 0.25% Ophthalmic Suspension","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle of KPI-121 0.25% Ophthalmic Suspension"]}],"interventions":[{"name":"KPI-121 0.25% Ophthalmic Suspension","otherNames":["Loteprednol etabonate"]},{"name":"Vehicle of KPI-121 0.25% Ophthalmic Suspension","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a documented clinical diagnosis of dry eye disease in both eyes\n\nExclusion Criteria:\n\n* Known hypersensitivity or contraindication to the investigational product(s) or components\n* History of glaucoma, Intraocular Pressure (IOP) \\>21 mmHg at the screening or randomization visits, or being treated for glaucoma in either eye.\n* Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in judgment of Investigator could confound study assessments or limit compliance; or have been exposed to an investigational drug within 30 days prior to screening.\n* In the opinion of the Investigator or study coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline/Visit 2 (Day 1) in Bulbar Conjunctival Hyperemia at Visit 4 (Day 15)","description":"Comparison of mean bulbar conjunctival hyperemia between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-4 grading scale. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4049","spread":"0.65062"},{"groupId":"OG001","value":"-0.1574","spread":"0.60704"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15)","description":"Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.53","spread":"20.636"},{"groupId":"OG001","value":"-9.16","spread":"17.924"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline/Visit 2 (Day 1) in Corneal Fluorescein Staining Score at Visit 4 (Day 15)","description":"Comparison of mean corneal fluorescein staining between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using methods developed by the National Eye Institute (NEI) Dry Eye Workshop in evaluating 5 regions of the cornea (superior, inferior, nasal, temporal and central) using a 0-3 grading scale, where 0 = no visible staining, 1 = Mild, 2 = moderate and 3 = severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.84"},{"groupId":"OG001","value":"-0.4","spread":"0.79"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline/Visit 2 (Day 1) Ocular Discomfort Severity at Visit 4 (Day 15) in the Subgroup of Participants With More Severe Ocular Discomfort","description":"Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse, in a sub-group of participants with more severe ocular discomfort at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.67","spread":"21.937"},{"groupId":"OG001","value":"-10.76","spread":"18.037"}]}]}]},{"type":"SECONDARY","title":"Change in Conjunctival Hyperemia Scores at Visit 4 (Day 15) in the Subgroup of Participants With More Severe Ocular Discomfort at Baseline (Day 1)","description":"Comparison of mean bulbar conjunctival hyperemia between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-4 grading scale. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4648","spread":"0.66770"},{"groupId":"OG001","value":"-0.2045","spread":"0.62567"}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects With ≥1 Improvement in Conjunctival Hyperemia at Visit 4 (Day 15)","description":"Proportion of subjects with ≥1 improvement from baseline in conjunctival hyperemia scores. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"189","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline/Visit 2 (Day 1) Conjunctival Hyperemia Scores at Visit 4 (Day 15) for the Mean of All Regions (Nasal, Temporal, Frontal)","description":"Comparison of mean bulbar conjunctival hyperemia between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-4 grading scale. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2980","spread":"0.59018"},{"groupId":"OG001","value":"-0.0421","spread":"0.51921"}]}]}]},{"type":"SECONDARY","title":"Change in Ocular Discomfort Severity Scores Prior to Visit 3 (Day 8) Minus the Mean of the Scores to Baseline/Visit 2 (Day 1)","description":"Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.12","spread":"16.880"},{"groupId":"OG001","value":"-4.81","spread":"14.851"}]}]}]},{"type":"SECONDARY","title":"Change in Ocular Discomfort Severity Scores Prior to Visit 3 (Day 8) Minus Baseline/Visit 2 (Day 1) in the Subgroup of Participants With More Severe Ocular Discomfort.","description":"Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.90","spread":"17.835"},{"groupId":"OG001","value":"-6.38","spread":"15.289"}]}]}]},{"type":"SECONDARY","title":"Change in Ocular Discomfort Severity Scores on Day 4 (Diary) Minus Baseline/Visit 2 (Day 1)","description":"Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.60","spread":"16.710"},{"groupId":"OG001","value":"-3.20","spread":"15.125"}]}]}]},{"type":"SECONDARY","title":"Change in Ocular Discomfort Severity Scores on Day 4 Day 4 (Diary) Minus Baseline/Visit 2 (Day 1) in the Subgroup of Participants With More Severe Ocular Discomfort","description":"Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse, in a sub-group of participants with more severe ocular discomfort at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.48","spread":"17.412"},{"groupId":"OG001","value":"-5.20","spread":"14.903"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline/Visit 2 (Day 1) in Conjunctival Hyperemia Scores With a Day 1 Conjunctival Hyperemia Score of ≥ 2 in the Subgroup of Participants With More Severe Ocular Discomfort","description":"Comparison of mean bulbar conjunctival hyperemia between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-4 grading scale in a sub-group of participants with more severe ocular discomfort at baseline.. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.47","spread":"0.631"},{"groupId":"OG001","value":"-0.22","spread":"0.577"}]}]}]},{"type":"SECONDARY","title":"Subjects With a Grade of 0 in Conjunctival Hyperemia Score at Visit 4 (Day 15)","description":"Comparison of mean bulbar conjunctival hyperemia between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-4 grading scale. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":459},"commonTop":["Installation site pain","Eye Irritation","Conjunctival hyperemia","Foreign Body Sensation","Lacrimination increased"]}}}